S&P 500   2,750.62 (+3.43%)
DOW   23,433.16 (+3.44%)
QQQ   200.69 (+2.18%)
AAPL   266.43 (+2.70%)
FB   174.04 (+3.08%)
MSFT   165.68 (+1.34%)
GOOGL   1,211.37 (+2.44%)
AMZN   2,036.99 (+1.26%)
CGC   15.13 (+4.34%)
BABA   195.05 (-1.49%)
MU   48.36 (+3.89%)
GE   7.30 (+3.84%)
TSLA   546.97 (+0.28%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.87 (+7.45%)
NFLX   370.81 (-0.55%)
BAC   23.38 (+5.55%)
GILD   74.69 (+0.03%)
DIS   100.76 (-0.47%)
S&P 500   2,750.62 (+3.43%)
DOW   23,433.16 (+3.44%)
QQQ   200.69 (+2.18%)
AAPL   266.43 (+2.70%)
FB   174.04 (+3.08%)
MSFT   165.68 (+1.34%)
GOOGL   1,211.37 (+2.44%)
AMZN   2,036.99 (+1.26%)
CGC   15.13 (+4.34%)
BABA   195.05 (-1.49%)
MU   48.36 (+3.89%)
GE   7.30 (+3.84%)
TSLA   546.97 (+0.28%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.87 (+7.45%)
NFLX   370.81 (-0.55%)
BAC   23.38 (+5.55%)
GILD   74.69 (+0.03%)
DIS   100.76 (-0.47%)
S&P 500   2,750.62 (+3.43%)
DOW   23,433.16 (+3.44%)
QQQ   200.69 (+2.18%)
AAPL   266.43 (+2.70%)
FB   174.04 (+3.08%)
MSFT   165.68 (+1.34%)
GOOGL   1,211.37 (+2.44%)
AMZN   2,036.99 (+1.26%)
CGC   15.13 (+4.34%)
BABA   195.05 (-1.49%)
MU   48.36 (+3.89%)
GE   7.30 (+3.84%)
TSLA   546.97 (+0.28%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.87 (+7.45%)
NFLX   370.81 (-0.55%)
BAC   23.38 (+5.55%)
GILD   74.69 (+0.03%)
DIS   100.76 (-0.47%)
S&P 500   2,750.62 (+3.43%)
DOW   23,433.16 (+3.44%)
QQQ   200.69 (+2.18%)
AAPL   266.43 (+2.70%)
FB   174.04 (+3.08%)
MSFT   165.68 (+1.34%)
GOOGL   1,211.37 (+2.44%)
AMZN   2,036.99 (+1.26%)
CGC   15.13 (+4.34%)
BABA   195.05 (-1.49%)
MU   48.36 (+3.89%)
GE   7.30 (+3.84%)
TSLA   546.97 (+0.28%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.87 (+7.45%)
NFLX   370.81 (-0.55%)
BAC   23.38 (+5.55%)
GILD   74.69 (+0.03%)
DIS   100.76 (-0.47%)
Log in

ASX:MYXMayne Pharma Group Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.25
MA: A$0.34
A$0.43
52-Week Range N/A
Volume7.47 million shs
Average Volume6.32 million shs
Market Capitalization$537.30 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products worldwide. It operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. The company also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited is based in Salisbury South, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.14 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-8-82092666

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$477.99 million
Book ValueA$0.65 per share

Profitability

Miscellaneous

Employees780
Outstanding Shares1,679,069,952
Market Cap$537.30 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MYX News and Ratings via Email

Sign-up to receive the latest news and ratings for MYX and its competitors with MarketBeat's FREE daily newsletter.


Mayne Pharma Group (ASX:MYX) Frequently Asked Questions

How were Mayne Pharma Group's earnings last quarter?

Mayne Pharma Group Ltd (ASX:MYX) released its earnings results on Friday, February, 22nd. The company reported $0.02 EPS for the quarter. View Mayne Pharma Group's earnings history.

Has Mayne Pharma Group been receiving favorable news coverage?

Media stories about MYX stock have trended very negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mayne Pharma Group earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutMayne Pharma Group.

Who are some of Mayne Pharma Group's key competitors?

What other stocks do shareholders of Mayne Pharma Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mayne Pharma Group investors own include Turquoise Hill Resources (TRQ), Aurora Cannabis (ACB), SUNDANCE ENERGY/S (SNDE), OrganiGram (OGI), Cronos Group (CRON), Westpac Banking (WBC), Telstra (TLS), Perseus Mining (PRU), Karoon Energy (KAR) and Crown Resorts (CWN).

Who are Mayne Pharma Group's key executives?

Mayne Pharma Group's management team includes the following people:
  • Mr. Scott Anthony Richards, MD, CEO & Exec. Director (Age 55)
  • Mr. Nick Freeman BCom, CA, Group CFO & Company Sec.
  • Mr. Stefan J. Cross, Pres of International Operations (Age 46)
  • Dr. Ilana Stancovski, Chief Scientific Officer & Head of European Market Devel.
  • Ms. Lisa Pendlebury, VP of Investor Relations & Communications

What is Mayne Pharma Group's stock symbol?

Mayne Pharma Group trades on the ASX under the ticker symbol "MYX."

How big of a company is Mayne Pharma Group?

Mayne Pharma Group has a market capitalization of $0.00 and generates $477.99 million in revenue each year. Mayne Pharma Group employs 780 workers across the globe. View additional information about Mayne Pharma Group.

What is Mayne Pharma Group's official website?

The official website for Mayne Pharma Group is http://www.maynepharma.com/.

How can I contact Mayne Pharma Group?

Mayne Pharma Group's mailing address is 1538 Main North Rd, ADELAIDE, SA 5106, Australia. The company can be reached via phone at +61-8-82092666.

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel